Science and Technology 科学技術 Vol.18 / #Coronavirus #コロナウイルス Vol.21

All the below links are in English.

取り急ぎ以下(黒字部分は内容事項一部抜粋ご参考まで)貼っておきます。

Science and Technology Vol.49 COVID19 vaccines materials AI,robotics
Science and Technology Vol.48 (incl 2019) telehealth coronavirus pandemics MachineLearning triage ventilator nurses startup chemicals GPS HorizonEU electrification
Science and Technology Vol.47 (incl 2019) digitalhealth PhysicalDistancing immunotherapy food molecular metal
Science and Technology Vol.46 (personal protective equipment (PPE) suppliers/manufacturers) 
Science and Technology Vol.45 telemedicine COVID19vaccine ventilators vitaminD kidneyinjury,AKI periosteum
Science and Technology Vol.44 GeorgeRutherford,UCSF MichaelOsterholm,UMN ArtificialIntelligence BreathTestingSystem,Shimadzu,TohokuUniversity
Science and Technology Vol.43 NobelPrizes/Physiology&Medicine/Physics/Chemistry
Science and Technology Vol.42 (miscellaneous) IgNobelPrizes heart-healthy lutein dexamethasone(Trump)
Science and Technology Vol.41 (miscellaneous) 3Dimaging/3Dprinting underwaterRobot water foodwaste nutrition planet
Science and Technology Vol.40 symptoms LosAngeles colleges,universities BigData,DataScience 3Dprinting,PPE ClimateChange Antarctica BraineatingAmoeba

#Coronavirus #コロナウイルス Vol.20(vaccines ワクチン) / U.S.A. アメリカ Vol.130(Massachusetts マサチューセッツ州 Vol.4 / New York ニューヨーク州 Vol.5: pharmaceutical corporations 製薬会社 – Moderna モデルナ社、Pfizer ファイザー社)

All the below links, excerpts, and tweets are in English.

cf. #Coronavirus #コロナウイルス Vol.19(vaccines ワクチン) / U.S.A. アメリカ Vol.129(New York ニューヨーク州 Vol.4 / Massachusetts マサチューセッツ州 Vol.3: pharmaceutical corporations 製薬会社 – Pfizer ファイザー社、Moderna モデルナ社)

昨日に引き続き取り急ぎ以下貼っておきます。

Multidose COVID-19 vaccines will test state tracking systems: People have to get two shots of the same type of vaccine (12/04/2020) | @verge
… Both take two doses, given a few weeks apart, and both could be circulating at the same time. And that’s just the two front-runners. Other multidose vaccines are still in the development pipeline.
There are a few ways states, doctors, and patients could keep the dosages straight, says Claire Hannan, executive director of the Association of Immunization Managers. In the simplest solution, everyone who gets a COVID-19 vaccine will also get a card that tells them which vaccine they had and when their next dose should be. But that’s the last line of defense in a complex vaccine tracking system. “As the backup to the backup to the backup, they’ll hand out cards,” Hannan says.
Ideally, the cards won’t be necessary because patients and doctors will be able to rely on electronic records and digital registry systems to keep track of who got which vaccine and when they got it. Through the pandemic, states have struggled with digital systems for other key areas, like COVID-19 testing – sometimes relying on fax machines and incomplete, handwritten forms to send information from testing sites to local health departments. But Hannan says the US immunization data collection systems at the state level are prepared to manage the expected crush of information from an unprecedented mass vaccination campaign like the one the country is about to start. Most tools were in place even before the pandemic hit. …
Big health systems with robust electronic health record management will likely have an easier time with this process than smaller clinics, says Howard Forman, a professor of public health, management, and economics at Yale University. “They’re used to keeping track of whether patients have had their followup appointments…
… Each state has its own Immunization Information System (IIS), a centralized registry that keeps track of every vaccine each person vaccinated in that state has received. Vaccination clinic software and electronic health records systems feed into those registries, which help doctors keep track of the vaccination records for individual patients, and also give each state big-picture data on vaccination rates in individual communities.
A state-level IIS can also notify doctors and patients when people are due for a second dose of a vaccine. They already use them to keep track of doses for the meningitis B vaccine…
The systems in place to track vaccinations today are much more advanced than they were in 2009, when the country struggled to distribute and track the H1N1 flu vaccine (which was only one shot), and electronic health records were rare. Only some states used their IIS programs. Many states had to rely on SurveyMonkey to connect with health care providers about vaccine delivery…

Moderna reaffirms 20M vaccine dose goal for December (12/04/2020) | @BosBizJournal
… The biotech has enlisted Italian firm Lonza to ramp up production to 500 million to one billion doses of the vaccine annually and Catalent Inc. to make all of the labels, seals and glass vials. Local life sciences unicorn Ginkgo Bioworks has also been helping Moderna optimize its production of raw materials for the drug.
Moderna has additionally hired another 150 employees to produce the vaccine out of its Norwood manufacturing facility. …

Moderna says its vaccine candidate has ‘potential’ to confer longer-term immunity (12/03/2020) | @MarketWatch
…National Institute of Allergy and Infectious Diseases…
The company said it remained confident it will have 20 million doses of the vaccine candidate available in the U.S. by the end of the year, and it expects to have between 100 million and 125 million doses available globally in the first quarter of next year.
Of these, between 85 million and 100 million will be available in the U.S. and between 15 million and 25 million will be available elsewhere…

Moderna’s 3-month data raise hopes for COVID-19 vaccine durability (12/04/2020) | @FierceBiotech
… Moderna shared details of the NEJM letter alongside an update on its effort to scale up production. …
Moderna Provides Updates on the Clinical Development and Production of Its COVID-19 Vaccine Candidate (12/03/2020) | @moderna_tx
… “mRNA-1273 produced high levels of binding and neutralizing antibodies that declined slightly over time, as expected, but they remained elevated in all participants three months after the booster vaccination.”…
Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination (12/03/2020) | @NEJM

What it feels like to get Moderna’s COVID-19 vaccine: “It’s not pleasant, but it’s definitely worth the risk of developing these side effects to make sure we can find an end to this pandemic.” (12/03/2020) | @BostonDotCom
Saginaw doctor who took part in Moderna vaccine trial seeks to reassure public (12/04/2020) | @MLive
Moderna Says COVID Vaccine Could Create Immunity For At Least Three Months (w Video; 12/04/2020) | @wbz
New data shows people who got Moderna vaccine still had antibodies 3 months later: The data came from a small number of phase 1 participants. (04/12/2020) | @ABCNews
Continuing COVID-19 vaccine trials may put some volunteers at unnecessary risk. Is that ethical? (w Video; 12/04/2020) | @USATODAY
No legal grounds for employers to force employees to get vaccinated, say experts (12/04/2020) | @CTVNews

Canada doubles Moderna vaccine order, daily COVID-19 cases could top 10,000 by January (12/04/2020) | @reuters
… Anand also said FedEx Corp and Innomar Strategies, a Canada-based division of AmerisourceBergen, had been contracted by the federal government to provide logistical support on vaccine delivery.

Moderna COVID vaccine best for Nunavut because of storage, shipping: top doctor (12/04/2020) | @CKOMNews
… Moderna’s vaccine is preferred because the Pfizer one requires cold storage and shipping would be too difficult in Nunavut. …

Two vaccines might get emergency approval this month. Here’s what you need to know (12/01/2020) | @latimes
What about those second doses?
The CDC’s vaccine tracking system will monitor who gets a first dose and will coordinate with Pfizer and Moderna on the shipment of the second doses. This means medical centers can administer all the doses they initially receive without having to hold onto half for the second shot.
How long before I can drive to my local pharmacy and get a vaccine?
If you’re healthy and a nonessential worker, you will have to wait. Most experts feel that the immunization effort in the United States will be in high gear by late spring and early summer of 2021…

Moderna to submit Covid-19 vaccine to FDA as full results show 94% efficacy (11/30/2020) | @statnews
… Moderna said that safety data is being reviewed continuously, but that there are no new serious safety concerns. The most common adverse events included site pain, fatigue, muscle or bone pain, headaches, and redness at the injection site. The reactions were more serious in the vaccine group after patients received a second dose. The results Pfizer and BioNTech released 12 days ago for their vaccine are roughly similar. …
… Each strand of synthetic mRNA is designed to encode for a protein found on the surface of SARS-CoV-2, the virus that causes Covid-19. Those mRNA strands enter the body’s cells and instruct them to produce that protein. The immune system then recognizes it as a foreign invader and produces antibodies that protect against Covid-19 if a person is later exposed to the virus.
The Covid-19 vaccine would be Moderna’s first product approved by the FDA and, assuming Pfizer’s vaccine is approved first, only the second mRNA medicine ever licensed. …

Moderna’s COVID-19 Vaccine Candidate Gets More Good News (w Voice; 11/30/2020) | @NPR
… Both use the same novel technology. Instead of injecting a weakened or dead virus, which is a common strategy for vaccines, these products are essentially small pieces of genetic material. When that’s injected into a person’s arm, it’s picked up by cells in the immune system. The cells read the genetic code and use that to produce a protein that is actually a key fragment of the coronavirus. The body then builds antibodies that latch onto that fragment, so if and when someone encounters the actual coronavirus, the body is primed to fight it off with antibodies. …

#Coronavirus #コロナウイルス Vol.19(vaccines ワクチン) / U.S.A. アメリカ Vol.129(New York ニューヨーク州 Vol.4 / Massachusetts マサチューセッツ州 Vol.3: pharmaceutical corporations 製薬会社 – Pfizer ファイザー社、Moderna モデルナ社)

All the below links, excerpts, and tweets are in English.
cf.
U.S.A. アメリカ Vol.107(New York ニューヨーク州 Vol.2: pharmaceutical corporations 製薬会社)
U.S.A. アメリカ Vol.113(Massachusetts マサチューセッツ州 Vol.2: pharmaceutical corporations 製薬会社)

取り急ぎ以下貼っておきます。

Pfizer And Moderna Face Their Biggest Challenge: Vaccinating The World (12/03/2020) | @IBDinvestors
… The obstacles can’t be overestimated, experts say. The vaccine supply chain is mindbogglingly complex. It involves local, state and federal authorities as well as hospitals, pharmacies and doctors’ offices.
The two most advanced coronavirus vaccines must be stored at specific temperatures and given in two doses several weeks apart. Stakeholders must keep tabs on who gets which vaccine and when. And don’t forget the public perception challenges of vaccinating people with drugs that went through clinical testing at record speeds.
Experts say 60% to 80% of the world must be vaccinated to achieve herd immunity. It will be many months – or years – before that happens as vaccine makers iron out supply constraints. Besides the Covid-19 vaccine companies themselves, a raft of other parties like drug distribution company McKesson (MCK) will be involved.
…the Centers for Disease Control and Prevention. The agency has overseen vaccine distribution in the U.S. for decades, including the national effort to vaccinate during the H1N1 influenza pandemic in 2009.
The coronavirus vaccination effort will probably look similar to that…
First, vaccination sites will need to enroll in the CDC’s Covid-19 vaccine distribution program. These sites will include doctors’ offices, clinics, hospitals and pharmacies. The program ensures these locations have enough well-trained staff, the right equipment and space to vaccinate large numbers of people.
Then, the vaccination sites will request doses of the coronavirus vaccine through a state agency…
Public health officials will then confirm the vaccination site is approved. If so, the order will head to the CDC. …
In August, the CDC tapped McKesson to help it distribute all coronavirus vaccines. …McKesson could rely on UPS, DHL and FedEx trucks to help it get the job done.
Pfizer, on the other hand, has a bigger challenge. The company’s coronavirus vaccine must be stored at ultracold temperatures. How cold? Penguins would find these temperatures chilly. …
Moderna’s vaccine can live in a standard refrigerator for 30 days. It can also be frozen for six months. Once thawed, providers must administer the vaccine within 12 hours – or toss it out. That creates a logistical challenge for transportation.
“Moderna will be heavily reliant on external suppliers…It will be using companies like CryoPort (CYRX), Stirling Ultracold and CH Robinson (CHRW) to work out cold chain logistics plus storage and shipping management.” …
…Pfizer has developed a special shipping container that can store the coronavirus vaccine for 10 days unopened…
The vaccine can be stored in an ultracold freezer for up to six months. It can stay in the shipping container for up to 30 days when replenished with dry ice every five days. Or, the drug can be stored for five days in a standard refrigerator.
…the strict storage requirements limit where Pfizer’s vaccine can be used. Those ultracold freezers cost about $20,000 apiece. …
…”Imagine getting one dose to Appalachia, a rural community. Now imagine having to come back and making sure everyone who got the first dose also gets the second one. That’s a challenge.”
…it’s likely the Pfizer vaccine will go to more populous locations with cold-storage capabilities. Coronavirus vaccine stock Moderna will probably send its drug to more rural communities.
…expects Pfizer to generate $875 million in coronavirus vaccine sales in 2020 and $7.25 billion in 2021. Eventually, that will trend down to $700 million to $800 million each year, depending on how often people need booster shots of the vaccine. …
“The drugmaker that gets this thing out first…Overnight, Pfizer becomes one of the most loved brands in America. It’s the McDonald’s (MCD) of the pharma industry.”
COVID19 vaccine-efforts

Pfizer to Ship Half as Many Coronavirus Vaccine Doses as Originally Planned in Initial Phase (12/03/2020) | @themotleyfool
…”Scaling up the raw material supply chain took longer than expected, and it’s important to highlight that the outcome of the clinical trial was somewhat later than the initial projection.”
BNT162b2, which showed an extremely high efficacy rate of 95% with no serious safety concerns in phase 3 clinical trials, has been submitted for similar approvals throughout the European Union, and with the U.S. Food and Drug Administration (FDA). In the wake of the U.K. approval, Pfizer and BioNTech anticipate decisions from other major regulators this month. …

Pfizer Scaled Back Vaccine Output Targets Earlier This Year (12/03/2020) | @business
…supply-chain problems caused the New York-based drugmaker to reduce the number of vaccines…led Pfizer shares to fall as much as 3.1% and caused the wider stock market to dip. The S&P 500 ended Thursday’s trading down 0.1%. …
Moderna Inc., which has also submitted a messenger RNA-based vaccine to the FDA for emergency clearance, said in a statement on Thursday it would have between 100 million and 125 million doses available globally in the first quarter of 2021. …

UK becomes the first to approve Pfizer-BioNTech Covid vaccine, rollout due next week (12/02/2020) | @CNBC
…with elderly people in care homes and medical workers first in line. …
“The government has today accepted the recommendation from the independent Medicines and Healthcare products Regulatory Agency (MHRA)…
Pfizer and BioNTech announced in July an agreement with the U.K. to supply 30 million doses of its mRNA-based vaccine…increased to 40 million doses in early October. As a two-dose vaccine, the U.K. will have enough doses to vaccinate around a third of its 66 million population. …
“I consider this decision to be problematic and recommend that EU Member States do not repeat the process in the same way. A few weeks of thorough examination by the European Medicines Agency is better than a hasty emergency marketing authorization of a vaccine,” said Peter Liese, a member of German Chancellor Angela Merkel’s party…

Pfizer supply chain challenges led to slashing COVID-19 vaccine production target – WSJ (12/03/2020) | @reuters,@YahooFinance
…anticipates producing 50 million doses of its COVID-19 vaccine this year. That is down from an earlier target of 100 million doses. Pfizer’s vaccine relies on a two dose regimen, meaning 50 million doses is enough to inoculate 25 million people. …
David Perdue bought Pfizer stock – a week before company said it would develop a vaccine (12/03/2020) | @salon

Science and Technology 科学技術 Vol.15 / #Coronavirus #コロナウイルス Vol.16(pharmaceutical products 医薬品 Vol.7:drugs 治療薬)

All the below links and excerpts are in English.

coronavirus及びdrugsと入れてグーグル検索して出て来たリンクと当方作成の抜粋を取り急ぎ以下のとおり貼っておきます。
cf. Science and Technology 科学技術 Vol.11 / #Coronavirus #コロナウイルス Vol.13(pharmaceutical products 医薬品 Vol.4:drugs 治療薬)

Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 (11/19/2020) | FDA
…an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
… Baricitinib is not authorized or approved as a stand-alone treatment for COVID-19. …
Baricitinib is a janus kinase inhibitor, which blocks the activity of one or more of a specific family of enzymes, interfering with the pathway that leads to inflammation. Baricitinib is a prescription oral tablet medication that is FDA-approved (and sold under the brand name Olumiant) for the treatment of moderately to severely active rheumatoid arthritis. …
Remdesivir is an FDA-approved (and sold under the brand name Veklury) intravenous antiviral drug for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Remdesivir also remains authorized for emergency use for the treatment of suspected or laboratory-confirmed COVID-19 in hospitalized pediatric patients weighing 3.5 kg (about 7.7 pounds) to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg. …
… Possible side effects of baricitinib in combination with remdesivir include serious infections, blood clots, changes in certain lab test results and allergic reactions.
The EUA was issued to Eli Lilly and Company. …

Antiviral Drugs That Are Approved or Under Evaluation for the Treatment of COVID-19 (11/03/2020) | NIH
see Table 2
Remdesivir
Chloroquine or Hydroxychloroquine With or Without Azithromycin
Lopinavir/Ritonavir and Other HIV Protease Inhibitors
Ivermectin

The Latest Research on COVID-19 Treatments and Medications in the Pipeline (11/18/2020) | @GoodRx
… Remdesivir is also being studied in combination with other medications. Early results reported that hospitalized COVID-19 patients who got both remdesivir and baricitinib (Olumiant) recovered about 1 day faster than those who only got remdesivir. Additionally, patients had a 30% higher chance of clinical improvement at day 15 when taking both medications together. The full data has not been shared yet.
Not all remdesivir studies have been promising. On October 15, 2020, a large, randomized study from the World Health Organization (WHO) found that remdesivir had little or no effect on death rate in hospitalized patients with COVID-19. The death rate was about 11% regardless of whether patients got remdesivir or not. These results have not been peer-reviewed yet. …

WHO suspends remdesivir from list of medicines (20/11/2020) | @RTE
… “The … panel found a lack of evidence that remdesivir improved outcomes that matter to patients such as reduced mortality, need for mechanical ventilation, time to clinical improvement, and others,” the guideline said. …
At the end of October, Gilead cut its 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, which is also known as Veklury.
The antiviral is one of only two medicines currently authorised to treat Covid-19 patients across the world…

Experimental drug given to Trump to treat covid-19 wins FDA clearance: But Regeneron’s antibody treatment is expected to be in short supply. (11/21/2020) | @washingtonpost
… The drug, made by Regeneron Pharmaceuticals, is designed to prevent infected people from developing severe illness. Instead of waiting for the body to develop its own protective immune response, the drug imitates the body’s natural defenses. It is the second drug of this type — called a monoclonal antibody — to be cleared for treating covid-19. The FDA authorized Eli Lilly & Co.’s drug on Nov. 9.
Regeneron’s drug is a cocktail of two monoclonal antibodies, called casirivimab and imdevimab. The FDA said in authorizing the cocktail that it may be effective in treating mild to moderate covid-19 in adults and children 12 or older, and is indicated for those at high risk of developing severe illness. Doctors hope the drugs will keep those patients from being hospitalized.
But as with the Lilly treatment, the Regeneron drug is a biological product that is complicated and time-consuming to make…
In a study published Oct. 28 in the New England Journal of Medicine, researchers said the Lilly cocktail lowered the risk of follow-up medical visits and reduced levels of virus in people with mild to moderate symptoms of covid-19. …
Through Operation Warp Speed, the Trump administration effort to speed up treatments and vaccines, the government has bought 300,000 doses each from Lilly and Regeneron at a cost of about $1,250 and $1,500 per dose, respectively, with an option to buy hundreds of thousands more. But that comes as the nation is approaching 200,000 new coronavirus cases each day.
In a sign of how quickly the supply could be used up as the pandemic surges across the country, 40 percent of the doses of Lilly’s bamlanivimab has already been allocated to states. …

Rheumatoid arthritis drug appears to help Covid patients in ICU: Trial suggests that tocilizumab improves outcomes for critically ill patients, say researchers (19/11/2020) | @guardian
… Tocilizumab, a medicine that dampens down inflammation, improved outcomes for critically ill patients…
…if confirmed by more trial data, the drug will be on track to become only the second effective therapy for the sickest Covid patients, following positive results for the steroid dexamethasone earlier this year. …
Dexamethasone, which costs about £5 per dose, was found in trials to cut the risk of death by a third for patients on ventilators. It is now part of standard care for Covid patients in hospital.
Tocilizumab costs between £500 and £1000 depending on whether patients receive one or two doses. …
cf. Science and Technology 科学技術 Vol.14 / #Coronavirus #コロナウイルス Vol.15(pharmaceutical products 医薬品 Vol.6:drugs 治療薬)

SKI Complex Identified as Target for Antiviral Drugs to Combat Coronaviruses (11/20/2020) | @Contagion_Live
…the University of Maryland School of Medicine…
…a group of proteins which regulates certain aspects of normal functions within a cell. … also seems to be involved with the replication of infectious diseases such as influenza and coronaviruses. The complex aids with a virus’ ability to replicate its genetic material, or RNA, within the cell.
The complex was identified originally in yeast, and when present, degraded its viral RNA. …

Science and Technology 科学技術 Vol.13 / #Coronavirus #コロナウイルス Vol.14(pharmaceutical products 医薬品 Vol.5:drugs 治療薬)

All the below links and excerpts are in English.

Convalescent plasma(回復期血漿療法)に係るリンクと当方作成の抜粋を取り急ぎ以下のとおり貼っておきます。

The FDA has authorized convalescent plasma treatment for coronavirus patients – but some scientists worry it’s too soon (08/26/2020) | @businessinsider
During the 1918 Spanish flu pandemic, doctors discovered they could treat sick patients with the blood of those who had already recovered. …
Antibodies develop in plasma, the liquid portion of blood – they’re part of our body’s natural response to a foreign pathogen. So the idea behind the treatment is to help sick people mount an antibody response to the virus by transferring plasma intravenously from those who already have antibodies.
“What we really need are drugs that, when given early, can prevent a symptomatic person from requiring hospitalization or very dramatically diminish the time that they’re symptomatic,” …
… Plasma must be transferred quickly from a donor to a recipient – and both must have compatible blood types. The quantity is also limited, since it depends on blood donations. …
A national study of 35,000 hospitalized coronavirus patients, which is still awaiting peer review, found that patients less than 80 years old who weren’t on a respirator and received plasma containing high levels of antibodies within three days of their diagnosis had a 35% lower mortality rate than those who were treated four or more days after their diagnosis.
The process of creating hyperimmune globulin involves pooling plasma from recovered patients and heat-treating it so that any remaining pathogens get destroyed. The result is a vial of medicine with consistent antibody levels that can easily be administered to patients. The drug focuses on the most common antibody found in blood ? immunoglobulin G (IgG) – which usually confers long-term immunity.
… The Mount Sinai Hospital … working with Emergent BioSolutions, a Maryland-based biopharmaceutical company, to develop a hyperimmune globulin product. …
… “The Fight Is In Us” … The coalition hopes to secure regulatory approval from the FDA by the end of 2020. …

Why we don’t know if convalescent plasma works to treat Covid-19 (08/29/2020) | @qz
… “There’s no money to be made in plasma,” says Jeffrey Henderson, a physician and infectious disease researcher at Washington University St. Louis. Because it’s a biological product, it can’t be patented or sold for a profit. As a result, no single research group or company has funded a large, randomized controlled trial of plasma, the highest standard of clinical evidence. …
It isn’t cheap: Between 2012 and 2018, the median cost of bringing a drug to market was $985 million, about $19 million of which goes to clinical research. Typically, drug companies are happy to invest. Once their product is approved, they can sell it at a price that makes up for the loss (and then some). …
…expanded access program (EAP), a network spearheaded by researchers at the Mayo Clinic in Rochester, Minnesota…
… Eventually, the EAP program got some funding from the US Biomedical Advanced Research and Development Authority…
…Albert Einstein College of Medicine in New York…

Takeda, CSL-led alliance starts scaling up production of COVID-19 plasma therapy as phase 3 kicks off: report (10/13/2020) | @fiercepharma
… The clinical batches were produced at Takeda’s U.S. facility in Georgia and CSL’s site in Bern, Switzerland. The National Institute of Allergy and Infectious Diseases in the U.S. is running the trial. …
Eli Lilly and Regeneron have reported encouraging results for their antibody cocktails, each of which combines two synthetic monoclonal antibodies. While those products have less antibody variety, they only used donated plasma to help identify the antibodies with the most promise in fighting COVID. …

DOD Awards $750,000 to Plasma Technologies, LLC for Manufacturing of Convalescent Plasma Products Using a Novel Process in Support of the U.S. COVID-19 Response (08/17/2020) | DOD
… The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) partnered with HHS and the Army Contracting Command – Aberdeen Proving Ground (ACC-APG), to select Plasma Technologies, LLC for this cooperative agreement. Plasma Technologies, LLC, a plasma biologics technology company, is located in Charleston, South Carolina. …

Plasma Therapy Global Market Report 2020-30: Covid 19 Growth and Change (07/30/2020) | CISION
Major players in the plasma therapy market are Takeda Pharmaceutical Company Limited, Bio Products Laboratory Ltd., Arthrex, Inc., Biotest AG, China Biologic Products Holdings, Inc., DePuy Synthes Companies, CSL Limited, Grifols, S.A., Octapharma, and Terumo BCT, Inc. …
The global plasma therapy market is expected to grow from $187.67 million in 2019 to $246.95 million in 2020 at a compound annual growth rate (CAGR) of 31.6%. The growth is mainly attributed to the COVID-19 outbreak and the urgent need to treat a growing number of cases. …
… In March 2020, Takeda Pharmaceutical Company Limited has initiated a plasma-therapy, Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG), which is termed as TAK-888 for treating COVID-19. The TAK-888 utilizes the plasma collected from convalescent donors who have been cured of COVID-19 and is administered to the patient suffering from COVID-19.

CoVIg-19 Plasma Alliance Builds Strong Momentum Through Expanded Membership and Clinical Trial Collaboration (05/07/2020) | @TakedaPharma
… In addition to those announced at its inception – Biotest, BPL, CSL Behring, LFB, Octapharma and Takeda – the Alliance welcomes new industry members ADMA Biologics, BioPharma Plasma, GC Pharma, and Sanquin. …
In parallel, the Alliance has confirmed it will work with the National Institute of Allergy and Infectious Diseases (NIAID) at the NIH to test the safety, tolerability and efficacy of the hyperimmune therapy in adult patients with COVID-19. This global study is currently anticipated to start in the summer…
“Hyperimmune globulin therapy has the potential to be one of the earliest treatment options for COVID-19, and we look forward to working with NIAID and health authorities to bring this therapy to patients as early as possible,” …
… To amplify awareness, the Alliance has gained support from large organizations outside of the plasma industry. Examples of those offering resources to the Alliance include Microsoft and Uber Health. Microsoft is providing technology support, including the Alliance website and the Plasmabot for donor recruitment. The Plasmabot streamlines the process for a potential donor to quickly gain information about their nearest collection center from across the member network. In parallel, Uber Health has agreed to donate 25,000 round-trip rides to transport potentially eligible donors to and from plasma collection centers. …

Global Plasma Leaders Collaborate to Accelerate Development of Potential COVID-19 Hyperimmune Therapy (04/06/2020) | @TakedaPharma
Biotest, BPL, LFB, and Octapharma have joined an alliance formed by CSL Behring (ASX:CSL/USOTC:CSLLY) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) to develop a potential plasma-derived therapy for treating COVID-19. The alliance will begin immediately with the investigational development of one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobulin medicine…

Trump admin funds plasma company based in owner’s condo (02/11/2020) | @ABCNews
Plasma Technologies LLC, Pepcid, ApiJect Systems America, Novavax
ThermoGenesis and ImmuneCyte Joint Venture Developing Several Convalescent Plasma and Antibody Therapeutic Approaches Against COVID-19, Featured on FOX40 and Other Local News Outlets (04/24/2020) | @biospace
Takeda, Other Firms Test Covid-19 Convalescent-Plasma Treatment: NIH funds study of high antibody concentrations combined with the antiviral remdesivir (10/08/2020) | @WSJ

Australia オーストラリア Vol.10(pharmaceutical corporations 製薬会社)

All the below links and tweets are in English.

取り急ぎ以下貼っておきます。

CSL(豪)の子会社
Pennsylvania Vol.11 (corporations: CSL Behring) / Australia Vol.29
UK Vol.173 (pharmaceutical corporations: Seqirus) / Australia Vol.30

上記リンク内に無い本日までのツイート


https://twitter.com/SamDForever1/status/1325970911258836992


https://twitter.com/DayofImmunology/status/1325371202831962112


https://twitter.com/CSLBehring/status/1322931444545703938


https://twitter.com/thalassaemiaTIF/status/1325715357408120835

ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの

U.S.A. アメリカ Vol.127(US Presidential Election 2020 米国大統領選挙)

All the below links are in English.

取り急ぎ以下貼っておきます。

US Presidential Election 2020 Vol.9 cspanNewsHourTIMENewsweekHuffPostvoxdotcom
US Presidential Election 2020 Vol.8 NPRpoliticothehilldrudgereportfeedBreitbartNewsDailyCaller
US Presidential Election 2020 Vol.7 CBSNewsNBCNewsCNNABCFoxNewsnytimeswashingtonpost
2020PresidentialResults_AP

cf.
9/1 US Presidential Election 2020 Vol.6 (The Hill)
9/1 US Presidential Election 2020 Vol.5 (Politico)
9/1 US Presidential Election 2020 Vol.4 (Politico)
8/31 US Presidential Election 2020 Vol.3 (American Enterprise Institute, Heritage Foundation)
8/31 US Presidential Election 2020 Vol.2 (Brookings Institution)
8/29 US Presidential Election 2020 Vol.1 (conventions)
10/29 U.S.A. Vol.126(Joe Biden For President)
10/29 U.S.A. Vol.125(Donald J. Trump for President)

Germany ドイツ Vol.5(pharmaceutical corporations 製薬会社)

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

Germany Vol.23 (pharmaceutical corporations: BioNTech)

上記リンク内に無い本日までのツイート


https://twitter.com/InvestFlanders/status/1323176383582011394


https://twitter.com/en_germany/status/1317834581048020993


ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの

U.K. イギリス Vol.31(pharmaceutical corporations 製薬会社)

All the below link and tweets are in English.

取り急ぎ以下貼っておきます。

UK Vol.170 (pharmaceutical corporations: GlaxoSmithKline)

上記リンク内に無い本日までのツイート


https://twitter.com/scibus/status/1321454739364728834
https://twitter.com/MSF_access/status/1321890170808008706
https://twitter.com/MSF_access/status/1321935282971807744


https://twitter.com/UN_SPHS/status/1321745134149656576


https://twitter.com/TomDoddFCDO1/status/1321891577317511169


ツイッター検索で 上記製薬会社名 及び Japan や 日本の5製薬会社各社名 を入れて出て来たもの


https://twitter.com/GSK/status/1275710004411187206
https://twitter.com/GSK/status/880055699820093440

Science and Technology 科学技術 Vol.11 / #Coronavirus #コロナウイルス Vol.13(pharmaceutical products 医薬品 Vol.4:drugs 治療薬)

All the below links and excerpts are in English.

リンクと当方作成の抜粋を取り急ぎ以下のとおり貼っておきます。

COVID-19 (coronavirus) drugs: Are there any that work? | @MayoClinic
Remdesivir
Antiviral drugs. In addition to remdesivir, other antiviral drugs being tested include favipiravir and merimepodib. …
Dexamethasone. …reduces the risk for deaths by about 30% for people on ventilators and by about 20% for people who needed supplemental oxygen. … Other corticosteroids, such as prednisone, methylprednisolone or hydrocortisone, may be used if dexamethasone isn’t available. However, their effectiveness isn’t yet known. …
Anti-inflammatory therapy.
Immune-based therapy. … Convalescent plasma is blood donated by people who’ve recovered from COVID-19. …mesenchymal stem cells and monoclonal antibodies.
・… Researchers study amlodipine and losartan. But it’s not yet…
Hydroxychloroquine and chloroquine. These malaria drugs… the FDA withdrew that authorization…
Drugs to prevent COVID-19.

The Latest Research on COVID-19 Treatments and Medications in the Pipeline (10/23/2020) | @GoodRx
Commonly used treatments for COVID-19 and therapies with emergency use authorizations (EUAs)
Remdesivir (Veklury)
Dexamethasone
Convalescent plasma
New treatments in early phase studies
Monoclonal antibodies (MABs) … Regeneron and Eli Lilly are two companies that both have MABs in development for COVID-19, currently called REGN-COV2 and LY-CoV555, respectively. …
Treatments that the NIH recommend against using for COVID-19
Hydroxychloroquine and chloroquine
Azithromycin … One research group looked at azithromycin in combination with hydroxychloroquine for COVID-19. They reported that 93% of patients cleared the virus after 8 days, but there was no control group so we don’t know if people would have cleared the virus on their own without the medications. There are concerns about potentially serious side effects when using azithromycin and hydroxychloroquine together. The NIH currently recommends against using azithromycin for COVID-19.
Tocilizumab (Actemra) and other IL-6 inhibitors … By blocking IL-6, tocilizumab helps to calm down the immune system and is believed to also help with managing cytokine storms.
Research on tocilizumab started with a study from France, which reported that people who got tocilizumab were less likely to require ventilation or die. Another study from Italy found that those who got tocilizumab had a lower death rate, though about the same percentage of patients from both groups needed ventilators. On the other hand, tocilizumab did not help COVID-19 patients with early-stage pneumonia. A phase 3 study from the manufacturer also found that tocilizumab did not help for hospitalized COVID-19 patients with severe pneumonia. …
… They showed that patients with severe symptoms who got Kevzara did worse compared to placebo, but patients who had even more severe (critical) symptoms improved compared to placebo. …
Kinase inhibitors … acalabrutinib (Calquence); baricitinib (Olumiant); ruxolitinib (Jakafi); tofacitinib (Xeljanz) …
Interferons
Kaletra (lopinavir/ritonavir)
Ivermectin
Repurposed medications with minimal COVID-19 data
Tamiflu (oseltamivir)
Avigan (favipiravir) and other antiviral medications … In vitro studies have shown that high doses of favipiravir were able to prevent human cells from being infected with SARS-CoV-2. …
Colcrys (colchicine)

Coronavirus Drug and Treatment Tracker (10/29/2020) | @nytimes
Coronavirus_Treatment-Tracker-nytimes
Blocking the Virus – Antivirals can stop viruses such as H.I.V. and hepatitis C from hijacking our cells. …
Remdesivir
Favipiravir
Molnupiravir
Recombinant ACE-2
Ivermectin
Oleandrin
Lopinavir and ritonavir
Hydroxychloroquine and chloroquine
Mimicking the Immune System -… Drugs might help people who can’t mount an adequate defense.
Convalescent plasma
Monoclonal antibodies
Interferons
Putting Out Friendly Fire – The most severe symptoms of Covid-19 are the result of the immune system’s overreaction to the virus. …
Dexamethasone and Other Corticosteroids
Cytokine Inhibitors
Blood filtration systems
Stem cells
Other Treatments
Pseudoscience and Fraud

Treatments for COVID-19: What helps, what doesn’t, and what’s in the pipeline (10/23/2020) | @HarvardHealth